- Home
- AEHL vs MYNZ Comparison
AEHL vs MYNZ Comparison
Compare AEHL & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEHL | MYNZ |
|---|---|---|
| Founded | 1993 | 2021 |
| Country | China | Germany |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 8.8M |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AEHL | MYNZ |
|---|---|---|
| Price | $2.01 | $1.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 10.0M | 197.9K |
| Earning Date | 12-26-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $98,773,000.00 | $659,935.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.99 | N/A |
| 52 Week Low | $1.13 | $0.92 |
| 52 Week High | $11.53 | $8.20 |
Technical Indicators
Market Signals| Indicator | AEHL | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 53.56 |
| Support Level | $2.88 | $1.00 |
| Resistance Level | $3.21 | $1.15 |
| Average True Range (ATR) | 0.39 | 0.08 |
| MACD | -0.13 | 0.02 |
| Stochastic Oscillator | 12.18 | 87.76 |
Price Performance
Historical ComparisonAbout AEHL Antelope Enterprise Holdings Limited
Antelope Enterprise Holdings Ltd operates in two reportable operating segments: 1) business management consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting, and 2) natural gas power generation, which was in the initial development stage. The business of the Company is engaged in the PRC and U.S.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.